ÂÜÀòÂÒÂ×

Dr. Greg Cosma is a scientific advisor at Immune-Onc Therapeutics and a previous Vice President Research and Early Development at Genentech. Greg has also worked as an Executive Director of Drug Safety Evaluation at Bristol-Myers Squibb and as a Research Fellow at Pfizer Pharmaceuticals. Prior to their work in the pharmaceutical industry, Dr. Cosma was an assistant professor at Colorado State University.

Dr. Cosma has over 25 years of experience in the pharmaceutical industry, with a focus on drug safety and development. Greg has played a leading role in several major organizational initiatives, including Project Agility at Genentech, which was designed to enhance innovation and pipeline delivery.

During their career, Dr. Cosma has authored or co-authored over 50 scientific papers and book chapters. Greg is a member of the American Society for Clinical Pharmacology and Therapeutics and the American Association for Cancer Research.

Greg Cosma received their PhD in Pharmacology and Toxicology from The University of Kansas. Greg then completed a post-doctoral fellowship at NYU Grossman School of Medicine. Greg is currently a Professor of Biochemistry at University of Illinois Urbana-Champaign.